Real-World Comparison of Effectiveness, Treatment Persistence, and Safety of First-Line Advanced Therapies at 1 Year for Ulcerative Proctitis

被引：0
|
作者：
Dalal, Rahul S. [1 ]
Clarke, Lindsay M. [1 ]
Carlin, Alex [1 ]
Cabral, Heidy [1 ]
Allegretti, Jessica R. [1 ]
机构：
[1] Harvard Med Sch, Brigham & Womens Hosp, Dept Med, Div Gastroenterol Hepatol & Endoscopy, Boston, MA USA
来源：
INFLAMMATORY BOWEL DISEASES | 2024年
关键词：
ulcerative colitis; inflammatory bowel disease; biologics; bio-na & iuml; ve; INFLAMMATORY-BOWEL-DISEASE;
D O I：
10.1093/ibd/izae215
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
In this retrospective cohort study, vedolizumab was associated with higher odds of steroid-free clinical remission at 1 year compared to anti-TNF agents for bio-na & iuml;ve patients with ulcerative proctitis.
引用
收藏
页数：4
相关论文
共 50 条
  • [1] Real World Comparison of Effectiveness, Durability, and Safety of First-Line Advanced Therapies for Ulcerative Proctitis
    Dalal, Rahul
    Clarke, Lindsay
    Carlin, Alexander
    Cabral, Heidy
    Allegretti, Jessica R.
    AMERICAN JOURNAL OF GASTROENTEROLOGY, 2024, 119 (10S): : S736 - S737
  • [2] Factors Driving Persistence to First-Line Advanced Therapies in Inflammatory Bowel Disease - A Real-World Study
    Santacroce, G.
    Lenti, M., V
    Lepore, F.
    Morda, F.
    Lo Bello, A.
    Aronico, N.
    Mengoli, C.
    Delliponti, M.
    Di Sabatino, A.
    JOURNAL OF CROHNS & COLITIS, 2025, 19
  • [3] A real-world comparison of the effectiveness and safety of vedolizumab and anti-TNF therapies in early treatment initiation with first-line biologic therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Brett, N.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF CROHNS & COLITIS, 2020, 14 : S092 - S094
  • [4] A REAL-WORLD COMPARISON OF THE EFFECTIVENESS AND SAFETY OF VEDOLIZUMAB AND ANTI-TNF THERAPIES IN EARLY TREATMENT INITIATION WITH FIRST-LINE BIOLOGIC THERAPY IN ULCERATIVE COLITIS: RESULTS FROM EVOLVE
    Mantzaris, Gerassimos J.
    Bressler, Brian
    Kopylov, Uri
    Bassel, Marielle
    Brett, Neil R.
    Colby, Chris
    Lopez, Claudia
    Saha, Sumit
    Kifnidi, Christina
    Agboton, Christian
    Adsul, Shashi
    Demuth, Dirk
    Luo, Michelle
    Wang, Song
    Yarur, Andres J.
    GASTROENTEROLOGY, 2020, 158 (06) : S405 - S405
  • [5] First-Line Treatment for Advanced Hepatocellular Carcinoma: A Three-Armed Real-World Comparison
    Mahn, Robert
    Glueer, Oscar Andre
    Sadeghlar, Farsaneh
    Moehring, Christian
    Zhou, Taotao
    Anhalt, Thomas
    Monin, Malte Benedikt
    Kania, Alexander
    Glowka, Tim R.
    Feldmann, Georg
    Brossart, Peter
    Kalff, Joerg C.
    Schmidt-Wolf, Ingo G. H.
    Strassburg, Christian P.
    Gonzalez-Carmona, Maria A.
    JOURNAL OF HEPATOCELLULAR CARCINOMA, 2024, 11 : 81 - 94
  • [6] A real-world comparison of the effectiveness and safety of vedolizumab and anti-tumor necrosis factor therapies in early treatment initiation with first-line biological therapy in ulcerative colitis: Results from EVOLVE
    Mantzaris, G.
    Bressler, B.
    Kopylov, U.
    Bassel, M.
    Colby, C.
    Lopez, C.
    Saha, S.
    Kifnidi, C.
    Agboton, C.
    Adsul, S.
    Demuth, D.
    Luo, M.
    Wang, S.
    Yarur, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 119 - 120
  • [7] REALASA: Real-world effectiveness assessment of first-line 5-ASA for the treatment of Ulcerative Colitis in Sweden
    Christophersen, B.
    Nielsen, L.
    Landeira, M.
    Guedes, S.
    JOURNAL OF CROHNS & COLITIS, 2025, 19 : I1423 - I1423
  • [8] Real-world comparison of the efficacy of first-line therapies and the influence of risk factors in advanced renal cell carcinoma
    Haack, Maximilian
    Neuberger, Stephanie
    Boerner, Jan Hendrik
    Ziewers, Stefanie
    Duwe, Gregor
    Dotzauer, Robert
    Haferkamp, Axel
    Mager, Rene
    DISCOVER ONCOLOGY, 2025, 16 (01)
  • [9] Racial differences in real-world outcomes of first-line therapies for advanced renal cell carcinoma
    Geynisman, Daniel M.
    John, William S.
    Miller, Taavy A.
    Asgarisabet, Parisa
    Guttenplan, Sarah B.
    Yin, Xin
    Savill, Kristin M. Zimmerman
    Mcallister, Lindsay
    Rosenblatt, Lisa
    ONCOLOGIST, 2024,
  • [10] Real-world effectiveness and safety of first-line osimertinib for EGFR-mutated advanced NSCLC in China (FLOURISH study)
    Zhou, J.
    Shen, L.
    Lv, D.
    Tang, K.
    Zhu, D.
    Zhao, Y.
    Wang, K.
    Wang, Y.
    Xing, L.
    Cui, J.
    Ding, L.
    Shi, X.
    Zheng, J.
    Zhou, J.
    ANNALS OF ONCOLOGY, 2023, 34 : S1689 - S1690
12345